PARSHALL B LYNNE 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) Director B. Lynne Parshall Sells 5,000 Shares
What Happened
B. Lynne Parshall, a director of Ionis Pharmaceuticals, sold 5,000 shares in an open-market transaction on February 11, 2026. The weighted-average sale price was $82.72 per share for total proceeds of $413,588. This was a sale (not a purchase), which is often routine insider selling.
Key Details
- Transaction date: 2026-02-11; Form 4 filed: 2026-02-13 (appears timely).
- Price: weighted average $82.72; individual trades ranged from $82.585 to $82.97.
- Shares sold: 5,000; total proceeds reported: $413,588.
- Shares owned after transaction: not specified in the provided filing details.
- Footnote F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted May 6, 2025.
- Footnote F2: The reported price is a weighted average; the filer will provide a breakdown of the number of shares sold at each price upon request.
Context
Sales made under a 10b5-1 plan are pre-arranged trading programs that allow insiders to sell shares according to a preset schedule and are generally viewed as routine rather than a direct signal of management’s view. This filing reports a straightforward open-market sale; no option exercises, gifts, or tax-withholding transactions are indicated.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-11$82.72/sh−5,000$413,588→ 56,344 total
Footnotes (2)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.585 to $82.97 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.